This meeting will discuss guidelines and best practices for both QT and non-QT-related cardiac safety issues, including the IC4-E-14 Guidance and the FDA Guidance on Evaluating Cardiovascular Risk for New Anti-diabetic Drugs.
Hotel Westin, Mumbai, India